ArticleJournal of the National Comprehensive Cancer Network : JNCCN2017
Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative.
Abstract read
In one paragraph
Article in Journal of the National Comprehensive Cancer Network : JNCCN, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Genetic Testing in a Population-Based Sample of Breast and Ovarian Cancer Survivors from the REACH Randomized Trial: Cost Barriers and Moderators of Counseling Mode.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2017Trial
- Real-World Actionability Analysis of Comprehensive Genomic Profiling Versus Single/Small-Gene Panels.Oncology and therapy · 2026Article
- Precision Therapeutics in Pancreatic Cancer: Emerging Targeted, Immune, and Antibody-Drug Conjugate Strategies Exemplified by Adagrasib, Dostarlimab, and Trastuzumab Deruxtecan.Journal of clinical medicine · 2026Review
- Risks and Implications of Multiple Actionable Pathogenic Germline Variants Discovered by Panel-Based Cancer Predisposition Testing.JCO precision oncology · 2025Article
- Precision Medicine in Hematologic Malignancies: Evolving Concepts and Clinical Applications.Biomedicines · 2025Review
- Genetic Test Utilization and Cost among Families of Children Evaluated for Genetic Conditions: An Analysis of USA Commercial Claims Data.Applied health economics and health policy · 2025Article
- Implementation of Cancer Genomics in the United States: Views of Payers and Other Stakeholders on Challenges and the Role of Payers in Solutions.JCO precision oncology · 2025Article
- Real-world clinical and economic outcomes for patients with advanced non-small cell lung cancer enrolled in a clinical trial following comprehensive genomic profiling via liquid biopsy.Journal of managed care & specialty pharmacy · 2024Article
- Review
- Perspectives of private payers on multicancer early-detection tests: informing research, implementation, and policy.Health affairs scholar · 2023Article
- Private Payer and Medicare Coverage Policies for Use of Circulating Tumor DNA Tests in Cancer Diagnostics and Treatment.Journal of the National Comprehensive Cancer Network : JNCCN · 2023Article
- Genetic counselors' experience with reimbursement and patient out-of-pocket cost for multi-cancer gene panel testing for hereditary cancer syndromes.Journal of genetic counseling · 2022Article
- Association between Health Insurance Type and Genetic Testing and/or Counseling for Breast and Ovarian Cancer.Journal of personalized medicine · 2022Article
- Genetic Testing and/or Counseling for Colorectal Cancer by Health Insurance Type.Journal of personalized medicine · 2022Article
- The Challenge of Genetic Variants of Uncertain Clinical Significance : A Narrative Review.Annals of internal medicine · 2022Review
- Statewide trends and factors associated with genetic testing for hereditary cancer risk in Arkansas 2013-2018.Hereditary cancer in clinical practice · 2022Article
- Influence of payer coverage and out-of-pocket costs on ordering of NGS panel tests for hereditary cancer in diverse settings.Journal of genetic counseling · 2022Article
- Hereditary cancer panel testing challenges and solutions for the latinx community: costs, access, and variants.Journal of community genetics · 2022Article
- US private payers' perspectives on insurance coverage for genome sequencing versus exome sequencing: A study by the Clinical Sequencing Evidence-Generating Research Consortium (CSER).Genetics in medicine : official journal of the American College of Medical Genetics · 2022Article
- Private Payer and Medicare Coverage for Circulating Tumor DNA Testing: A Historical Analysis of Coverage Policies From 2015 to 2019.Journal of the National Comprehensive Cancer Network : JNCCN · 2020Article
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Julia R TrosmanUCSF Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), Department of Clinical Pharmacy, University of California, San Francisco, San Franscisco, California
Christine B WeldonUCSF Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), Department of Clinical Pharmacy, University of California, San Francisco, San Franscisco, California
Michael P DouglasUCSF Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), Department of Clinical Pharmacy, University of California, San Francisco, San Franscisco, California
Allison W KurianDepartments of Medicine and of Health Research and Policy, Stanford University School of Medicine, Stanford, California
R Kate KelleyUCSF Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), Department of Clinical Pharmacy, University of California, San Francisco, San Franscisco, California
Patricia A DeverkaAmerican Institutes for Research, Chapel Hill, North Carolina
Kathryn A PhillipsUCSF Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), Department of Clinical Pharmacy, University of California, San Francisco, San Franscisco, California
Funding
Risk-Benefit Trade-Offs for Whole Genome SequencingR01HG007063 · NHGRI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PHILLIPS, KATHRYN A · 2013 to 2016
$2.5MNHGRI NIH HHS R01 HG007063
Abstract
PubMed holds no abstract for this paper.
Indexed as
Insurance CoverageGenetic TestingHealth Services AccessibilityHumansInsurance, Health, ReimbursementNeoplasmsPrecision MedicineQualitative ResearchRisk AssessmentUnited States
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.